This is a summary of the European public assessment report (EPAR) for Caprelsa. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Caprelsa. For practical information about using Caprelsa, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Caprelsa is indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. Caprelsa is indicated in adults, children and adolescents aged 5 years and older. For patients in whom re-arranged-during-transfection(RET) mutation is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision.
Therapeutic Area (MeSH)
ATC Code
L01XE
ATC Item
蛋白激酶抑制剂
Pharmacotherapeutic Group
Antineoplastic and immunomodulating agents
Active Substance (Summary)
INN / Common Names
EMA Name
Caprelsa
Medicine Name
Caprelsa
Aliases
N/A